With hopes for antibodies waning, the NIH will test Novartis partner's novel antiviral in hospitalized Covid-19 patients
After a slew of failures, the NIH’s ACTIV-3 trial for hospitalized Covid-19 patients has earned its reputation as a graveyard for big-name antibodies. Now, with its options running out, the NIH is turning to a Novartis-backed antibody alternative — but is this déjà vu all over again?
Molecular Partners and partner Novartis will try out their “trispecific” DARPin antiviral ensovibep in ACTIV-3, the hospitalized mild-to-moderate patient arm of the NIH’s ACTIV “master protocol” against Covid-19, the pair said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.